BIO Share Price

Open 16.25 Change Price %
High 16.64 1 Day -0.05 -0.31
Low 16.15 1 Week -0.30 -1.82
Close 16.20 1 Month -0.16 -0.98
Volume 4236 1 Year -0.13 -0.80
52 Week High 18.92
52 Week Low 12.03
BIO Important Levels
Resistance 2 16.65
Resistance 1 16.47
Pivot 16.33
Support 1 15.93
Support 2 15.75
ETR Germany Most Active Stocks
EOAN 6.43 4.72%
EOAN 6.43 4.72%
DBK 16.39 7.26%
DBK 16.39 7.26%
CBK 6.99 6.07%
CBK 6.99 6.07%
RWE 11.92 1.53%
RWE 11.92 1.53%
DTE 15.07 1.14%
DTE 15.07 1.14%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
R3Q 0.12 20.00%
5M71 39.00 13.70%
HBC2 38.40 10.31%
BVB 5.22 9.66%
SFD1 0.57 9.62%
BNT1 9.00 8.70%
IES 2.25 8.17%
IES 2.25 8.17%
TIN 0.58 7.41%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
EMQ 0.02 -50.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
N7E 0.04 -20.00%
DUL 39.00 -13.33%
DUL 39.00 -13.33%
M6YA 2.10 -12.86%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 3
As on 6th Dec 2016 BIO Share Price closed @ 16.20 and we RECOMMEND Sell for LONG-TERM with Stoploss of 16.30 & Sell for SHORT-TERM with Stoploss of 16.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for December
1st Target up-side 16.87
2nd Target up-side 17.55
3rd Target up-side 18.23
1st Target down-side 14.93
2nd Target down-side 14.25
3rd Target down-side 13.57
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.